News and features

Viruses have shown renewed promise in the treatment for cancer, after new research has shown they retain their cancer-killing ability even when injected into the bloodstream.

Top researchers waved off a group of our most dedicated supporters as they embarked on a new cycling challenge, which has already raised over £12,500 for the ICR.

A group of men with especially aggressive prostate cancer may respond unusually well to immunotherapy, a major new study reports.

Scientists have used artificial intelligence to predict how cancers will progress and evolve – so that doctors can design the most effective treatment for each patient.

Blood tests could predict how long it takes until bowel cancer returns based on the same principle used in forecasting the weather, a new study has found.

The ICR responds to draft decision not to recommend CAR T cell therapy for two types of non-Hodgkin lymphoma.

The Institute of Cancer Research, London, is making the following statement regarding an investigation we have conducted into allegations of bullying by a staff member.

Sophisticated new computer software can be used to predict how cancers may respond to a new drug before it has ever been given to patients.

Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

Researchers have identified a vulnerability in some breast cancer cells of a certain type – called triple negative breast cancer – that could be exploited by future targeted drugs.

Scientists have developed a complex mathematical model that uses a snapshot of tumours’ genetic code to reach back in time, revealing its evolutionary history.

Members of the ICR’s Discovery Club, our high-level giving club of visionary supporters, learned about the difference that philanthropy is making to people with cancer at an event in the impressive surroundings of Two Temple Place, in Central London.